Advertisement

Imetelstat Leads to Durable Red Blood Cell Transfusion Independence

Mar 03, 2024

REFERENCES & ADDITIONAL READING

Platzbecker U, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2024 Jan 20;403(10423):248]. Lancet. 2024;403(10423):249-260. doi:10.1016/S0140-6736(23)01724-5

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
Advertisement